glp-1 obesity drug news today september 2025 A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio Beyond GLP-1: the next wave
Description
Advertise With Us Please Contact Us
According to the World Health Organization (WHO), the global prevalence of obesity has nearly tripled since 1975
These findings place GLP-1 receptor agonists among the most effective pharmacological strategies currently available for reducing cardiometabolic and renal risk in high-risk populations
Our guide on tirzepatide not working anymore covers the troubleshooting steps, but sometimes the answer is simply that a different mechanism works better for your biology
J Biol Chem (2013) 288:3558191
Nature 546 , 248253 (2017)
